Zealand Pharma A/S - Product Pipeline Review - Q1 2011

Global Markets Direct, May 2011, Pages: 35

Zealand Pharma A/S – Product Pipeline Review – Q1 2011

Summary

Global Market Direct’s pharmaceuticals report, “Zealand Pharma A/S - Product Pipeline Review - Q1 2011” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Zealand Pharma A/S - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Zealand Pharma A/S human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Zealand Pharma A/S with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Zealand Pharma A/S’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Zealand Pharma A/S’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Zealand Pharma A/S in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Zealand Pharma A/S’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Zealand Pharma A/S.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Zealand Pharma A/S and identify potential opportunities in those areas.

List of Tables
List of Figures
Zealand Pharma A/S Snapshot
Zealand Pharma A/S Overview
Key Information
Key Facts
Zealand Pharma A/S – Research and Development Overview
Key Therapeutic Areas
Zealand Pharma A/S – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Zealand Pharma A/S – Pipeline Products Glance
Zealand Pharma A/S Clinical Stage Pipeline Products
Phase I Products/Combination Treatment Modalities
Zealand Pharma A/S–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Zealand Pharma A/S – Drug Profiles
ZP1609
Product Description
Mechanism of Action
R&D Progress
ZP1848
Product Description
Mechanism of Action
R&D Progress
ZP2307
Product Description
Mechanism of Action
R&D Progress
ZP2435
Product Description
Mechanism of Action
R&D Progress
ZP2929
Product Description
Mechanism of Action
R&D Progress
Zealand Pharma A/S – Pipeline Analysis
Zealand Pharma A/S – Pipeline Products by Therapeutic Class
Zealand Pharma A/S - Pipeline Products By Target
Zealand Pharma A/S – Pipeline Products by Route of Administration
Zealand Pharma A/S – Pipeline Products by Molecule Type
Zealand Pharma A/S – Recent Pipeline Updates
Zealand Pharma A/S - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
ZP2435
Rotigaptide
Zealand Pharma A/S – Locations And Subsidiaries
Head Office
Financial Deals Landscape
Zealand Pharma A/S, Deals Volume Summary, 2004 to YTD 2011
Zealand Pharma A/S, Deals Summary By Region, 2004 to YTD 2011
Zealand Pharma A/S, Deals Summary, 2004 to YTD 2011
Zealand Pharma A/S Detailed Deal Summary
Venture Financing
Zealand Pharma Secures $17 Million In Second Tranche Of Series C financing
Equity Offering
Zealand Pharma Completes Right Issue Of $37 Million
Zealand Pharma Withdraws Initial Public Offering
Zealand Pharma Expands Collaboration Agreement With Wyeth Pharmaceuticals
Licensing Agreements
Zealand Pharma Enters Into Licensing Agreement With Helsinn Healthcare
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Zealand Pharma A/S – Pipeline by Therapy Area and Indication, 2011
Zealand Pharma A/S – Pipeline by Stage of Development, 2011
Zealand Pharma A/S – Monotherapy Products in Pipeline, 2011
Zealand Pharma A/S - Phase I, 2011
Zealand Pharma A/S - Pipeline By Therapeutic Class, 2011
Zealand Pharma A/S - Pipeline By Target, 2011
Zealand Pharma A/S – Pipeline By Route of Administration, 2011
Zealand Pharma A/S – Pipeline By Molecule Type, 2011
Zealand Pharma A/S – Recent Pipeline Updates, 2011
Zealand Pharma A/S - Discontinued Pipeline Products, 2010
Zealand Pharma A/S, Deals Summary, 2004 to YTD 2011
Zealand Pharma A/S, Deals Summary by Region, 2004 to YTD 2011
Zealand Pharma A/S, Deals Summary, 2004 to YTD 2011

List of Figures
Zealand Pharma A/S – Pipeline by Therapy Area and Indication, 2011
Zealand Pharma A/S – Pipeline by Stage of Development, 2011
Zealand Pharma A/S – Monotherapy Products in Pipeline, 2011
Zealand Pharma A/S – Pipeline By Therapeutic Class, 2011
Zealand Pharma A/S - Pipeline By Target, 2011
Zealand Pharma A/S – Pipeline By Route of Administration, 2011
Zealand Pharma A/S – Pipeline By Molecule Type, 2011

Customers who bought this item also bought

• Top Five Global Software Companies: Performance, Strategies and Competitive Analysis
• Apple, Inc. - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Hewlett-Packard Company - Strategies, Financial Outlook and Competitive Benchmark Analysis
• SunGard - Profile - US
• Scientific Games Corporation - Company Analysis
• Insight into Samsung Electronics' Notebook PC Business Model
• eBay - Strong Execution
• Amazon - Point of Realization in 2013?
• Ixia - Company Analysis
• Accenture - Profile - US